Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Dodge & Cox

Dodge & Cox raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.9% in the third quarter, Holdings Channel reports. The fund owned 4,550,845 shares of the biopharmaceutical company’s stock after buying an additional 724,562 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.4% of Dodge & Cox’s portfolio, making the stock its 29th biggest holding. Dodge & Cox’s holdings in Regeneron Pharmaceuticals were worth $2,558,804,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Caitlin John LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $34,000. Traub Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $38,000. Finally, Berbice Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock worth $4,142,738 over the last quarter. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $745.77 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The firm has a market capitalization of $78.84 billion, a P/E ratio of 17.94, a PEG ratio of 2.01 and a beta of 0.41. The company’s fifty day moving average is $769.73 and its two-hundred day moving average is $694.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the business earned $12.07 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Wall Street Analyst Weigh In

Several brokerages have commented on REGN. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Finally, Evercore increased their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.